2026-01-21 - Analysis Report
# Comprehensive Analysis

## Company Overview

Novo Nordisk is a global healthcare company that discovers, develops, and manufactures innovative pharmaceutical solutions for diabetes and other chronic diseases.

## Return Rate Comparison with S&P 500 (VOO)

| Ticker | Return Rate (%) | Divergence |
| --- | --- | --- |
| NVO | 49.25% | -40.00% (-19.40% relative to max-min range) |
| VOO (S&P 500) | 89.37% |  |

The cumulative return of NVO is significantly lower than VOO, indicating a divergence of -40.00%.

## Alpha, Beta Analysis 

| Period | CAGR | MDD | Alpha | Beta | Market Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 0.0% | 19.0% | -5.0% |  | 102.4 |
| 2017-2019 | 37.0% | 13.6% | 20.0% |  | 128.6 |
| 2018-2020 | 1.0% | 12.5% | -20.0% |  | 155.2 |
| 2019-2021 | 58.0% | 13.0% | 15.0% |  | 248.8 |
| 2020-2022 | 58.0% | 23.2% | 60.0% |  | 300.7 |
| 2021-2023 | 87.0% | 23.2% | 86.0% |  | 459.7 |
| 2022-2024 | 18.0% | 40.5% | -1.0% |  | 382.2 |
| 2023-2025 | -52.0% | 59.7% | -114.0% |  | 226.1 |

**Note:** Market capitalization (Market Cap) is in billions of USD.

## Recent Stock Price Fluctuations

|  | Close | 5-day SMA | 20-day SMA | 60-day SMA |
| --- | --- | --- | --- | --- |
| Price | $60.68 | $59.74 | $55.07 | $50.85 |

The recent stock price fluctuations indicate a potential downward trend, especially with the 5-day SMA and 20-day SMA below the current price.

## RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence

| Indicator | Value |
| --- | --- |
| Market Risk Indicator (MRI) | 0.80 |
| RSI | 74.02 |
| PPO | 0.89 |

**Analysis:** The MRI indicates a Medium Risk investment. The RSI value of 74.02 suggests that the stock is overbought. The PPO value of 0.89 indicates a positive momentum.

## Recent News & Significant Events

*   [2026-01-06] Novo Nordisk: NVO Stock To $100? - Forbes
*   [2026-01-20] Lobbying Update: $2,120,000 of NOVO NORDISK INC. lobbying was just disclosed - Quiver Quantitative
*   [2026-01-06] Warning: This Skyrocketing Stock Has a Hidden Risk - The Motley Fool
*   [2026-01-20] NVO Stock Today: January 20 Tariff Jitters Test Novo Nordisk Rally - Meyka
*   [2026-01-20] ‘Sales and Earnings to Shrink in 2026’ TD Cowen Says of Novo Nordisk Stock (NVO) - TipRanks
*   [2026-01-16] NVO Stock Is Rising Pre-Market – What Is The Wegovy News Driving Novo Nordisk Shares? - Stocktwits

## Analyst Opinions

*   **Analyst Consensus:**
    *   Buy
    *   Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
    *   Opinions: 11
    *   Target Price (avg/high/low): 56.36 / 73.95 / 41.94

## Comprehensive Analysis

Based on the provided data, NVO has shown significant fluctuations in its return rate compared to the S&P 500 (VOO). The stock's Alpha and Beta values indicate a relatively stable performance, but the recent stock price fluctuations suggest a potential downward trend. The MRI, RSI, and PPO values indicate a Medium Risk investment, with the stock being overbought and showing positive momentum. Recent news and events suggest potential risks and uncertainties affecting the stock's performance.

Overall, the comprehensive analysis indicates that NVO is a Medium Risk investment opportunity with potential risks and uncertainties. Investors should carefully consider these factors before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.